- For the third consecutive year, an analysis of the most promising new drugs of the year was presented.
- In first position is a formula created against Alzheimer’s.
- It is awaiting FDA approval but is expected to generate $3 billion in sales over the next five years.
Health always advances hand in hand with innovation. Nothing is static because new drugs are developed every day that promise to be an alternative against a specific disease or condition. Although in order to be within the reach of patients, it is first necessary to overcome a long and strict path. The objective is to verify the correct functioning of each one.
All the steps to develop new drugs
In this sense, the pharmaceutical industry invests large amounts of money to develop new molecules. While another of the problems is that only a minimum amount manages to reach the final stage. Most remain in one of the previous stages because they are not highly effective or generate more harm than benefits.
It all starts with the preclinical trials. In this stage, research is carried out and ideas for possible new drugs are presented. The most promising are tested in animal models to see if they can really work.
The projects that advance to the Phase 1 clinical trials are applied to dozens of human volunteers. The maximum objective is to repeat the good results but it is also a stage that helps to determine the correct dose of each drug.
Then follow the phase 2 where the improved versions are now tested on hundreds of volunteers. If, in the end, the operation is optimal, then we advance to the Phase 3 where the trials are with thousands of people.
In this case, there are some new drugs who have already passed the entire previous process and are now waiting to obtain the sanitary registry. It is the last stage to be able to be commercialized.
With this in mind, for the third consecutive year The Fierce Pharma portal presented an analysis of the most promising new drugs in the world. The list corresponds to 2023 and includes 10 formulas developed against various diseases.
- Lecanemab – Alzheimer’s disease
- SRP-9001 – Gene therapy for Duchenne muscular dystrophy
- Intravitreal Pegcetacoplan – Complement factor C3 inhibitor for atrophy
- Donanemab – Anti-amyloid monoclonal antibody for Alzheimer’s disease
- RSVPreF3 OA – Vaccine for older adults against Respiratory Syncytial Virus
- Epcoritamab – Lymphoma
- Zuranolone – Major depressive disorder and/or postpartum depression
- Mirikizumab – Crohn’s disease
- Etrasimod – Ulcerative colitis
- Sotaterception – Pulmonary arterial hypertension
One of the striking aspects is that lecanemab aims to be the drug with the highest sales of the next five years. This option developed by Eisai and Biogen is awaiting approval from the United States Food and Drug Administration (FDA). Although according to their manufacturers, it is expected that during the following years it will generate sales of around 3 billion dollars.
Within the list also appears SRP-9001which has not yet obtained a definitive name but consists of a gene therapy for Duchenne muscular dystrophy. This formula was created by Roche and during the next five years it expects to generate sales of 2.2 billion dollars.
While the third position is for intravitreal Pegcetacoplan. It consists of a complement factor C3 inhibitor for atrophy developed by Apellis. It is awaiting FDA approval, and once it does, it could generate $2 billion in sales by 2028.
Also read:
The most promising clinical trials in Medicine for 2023
The 10 most surprising medical news of 2022: From innovative drugs to advances against cancer
These are the new medicines that the WHO recommends for nuclear emergencies